Tryptophan metabolism contributes to radiation-induced immune checkpoint reactivation in glioblastoma.

Pravin Kesarwani,Antony Prabhu,Shiva Kant,Praveen Kumar,Stewart F. Graham,Katie L. Buelow,George D. Wilson,C. Ryan Miller,Prakash Chinnaiyan,Katie L Buelow,Christopher Ryan Miller,George D Wilson,Stewart F Graham
DOI: https://doi.org/10.1158/1078-0432.CCR-18-0041
IF: 13.801
2019-10-03
Clinical Cancer Research
Abstract:Immune checkpoint inhibitors designed to revert tumor-induced immune suppression have emerged as potent anti-cancer therapies. Tryptophan metabolism represents an immune checkpoint and targeting this pathway's rate limiting enzyme IDO1 is actively being investigated clinically. Here, we studied the intermediary metabolism of tryptophan metabolism in glioblastoma and evaluated the activity of the IDO1 inhibitor GDC-0919, both alone and in combination with radiation (RT). Experimental Design: LC/GC-MS and expression profiling was performed for metabolomic and genomic analyses of patient-derived glioma. Immune competent mice were injected orthotopically with genetically engineered murine glioma cells and treated with GDC-0919 alone or combined with RT. Flow-cytometry was performed on isolated tumors to determine immune consequences of individual treatments.
oncology
What problem does this paper attempt to address?